DexCom IncDXCM
▲ PositiveCapitalrelevance
Beats Q2 revenue and EPS estimates, raises full-year guidance.
Impact on stocks 1
Biotech & Genomic Medicine
DexCom IncDexCom reported second-quarter revenue of $1.31 billion, beating analyst estimates of $1.29 billion and growing 13.1% year on year. Adjusted earnings per share came in at $0.70, topping the consensus of $0.61 by 15.1%, while adjusted EBITDA of $421.3 million exceeded the $390.7 million forecast. The company slightly raised its full-year revenue guidance to $5.22 billion at the midpoint from $5.21 billion. Management attributed the performance to strong global demand for its continuous glucose monitoring solutions, expanded reimbursement for type 2 diabetes patients not on insulin, and rapid adoption of the G7 15-day system. DexCom also highlighted the submission of CONNECT trial data to CMS for potential Medicare coverage expansion and ongoing investments in its Ireland manufacturing facility and digital health capabilities.
DexCom IncBeats Q2 revenue and EPS estimates, raises full-year guidance.